CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 65 filers reported holding CABALETTA BIO INC in Q4 2021. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,214,008 | +36.9% | 145,467 | +16.1% | 0.00% | – |
Q2 2023 | $1,617,572 | +659.9% | 125,296 | +386.8% | 0.00% | – |
Q1 2023 | $212,878 | -10.6% | 25,741 | 0.0% | 0.00% | – |
Q4 2022 | $238,104 | +1884.2% | 25,741 | +36.8% | 0.00% | – |
Q3 2022 | $12,000 | -40.0% | 18,822 | 0.0% | 0.00% | – |
Q2 2022 | $20,000 | -56.5% | 18,822 | -17.0% | 0.00% | – |
Q1 2022 | $46,000 | +17.9% | 22,674 | +120.2% | 0.00% | – |
Q4 2021 | $39,000 | -68.8% | 10,295 | 0.0% | 0.00% | – |
Q3 2021 | $125,000 | +40.4% | 10,295 | 0.0% | 0.00% | – |
Q2 2021 | $89,000 | -84.2% | 10,295 | -79.7% | 0.00% | – |
Q1 2021 | $563,000 | -8.9% | 50,730 | +2.4% | 0.00% | – |
Q4 2020 | $618,000 | +10.8% | 49,558 | -3.8% | 0.00% | – |
Q3 2020 | $558,000 | +14.1% | 51,507 | +17.6% | 0.00% | – |
Q2 2020 | $489,000 | +217.5% | 43,816 | +108.1% | 0.00% | – |
Q1 2020 | $154,000 | -12.5% | 21,051 | +67.6% | 0.00% | – |
Q4 2019 | $176,000 | – | 12,561 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |